Galectin Therapeutics announces positive preliminary results from phase 1b clinical trial
Galectin Therapeutics announced additional preliminary clinical data from cohort 3 of an investigator-initiated Phase 1b clinical trial of GR-MD-02 used in combination with KEYTRUDAź (pembrolizumab) in patients with metastatic melanoma for which KEYTRUDA is indicated. September 20, 2018